IP Library › Granted Patent US 12,077,544
Granted Patent B2
US 12,077,544 · App. 18/094,929 · Granted Sep 3, 2024

Irreversible inhibitors of menin-MLL interaction

Inventors: Thomas Butler (Redwood City, CA); Jim Palmer (Warrandyte, AU); Ravi Upasani (San Jose, CA); Matthew Welsch (New Haven, CT); Sridhar Vempati (Edison, NJ); Brendan Kelly (Castlecomer, IE); Edward Painter (Chappaqua, NY)
Assignee: Biomea Fusion, Inc.
C07D487/04C07D401/04C07D401/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,077,544
App. No.
18/094,929
Granted
Sep 3, 2024
Kind
B2
Abstract

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.

Claims (40)

1. A compound selected from the group consisting of:

or a salt thereof.

2. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

3. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

4. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

5. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

6. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

7. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

8. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

9. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

10. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

11. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

12. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

13. The compound according to claim 1 , wherein the compound is:

or a salt thereof.

14. The compound according to claim 1 , wherein the compound is:

or a salt thereof.

15. The compound according to claim 1 , wherein the compound is:

or a salt thereof.

16. The compound according to claim 1 , wherein the compound is:

or a salt thereof.

17. The compound according to claim 1 , wherein the compound is:

or a salt thereof.

18. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

19. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

20. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2023
From: UPASANI, RAVI; PALMER, JIM; VEMPATI, SRIDHAR; BUTLER, THOMAS; KELLY, BRENDAN; PAINTER, EDWARD; WELSCH, MATTHEW
To: BIOMEA FUSION, LLC
Reel/Frame 063347/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2023
From: BIOMEA FUSION, LLC
To: BIOMEA FUSION, INC.
Reel/Frame 063363/0254 →
Continuity (4)
Division 17352146 · Jun 18, 2021
Continuation 16732226 · Dec 31, 2019
Provisional Application 62786842 · Dec 31, 2018
Related Publication 20230227458A1 · Jul 20, 2023